Status:
UNKNOWN
Safety Profiles of Liver Biopsy in Hemodialysis Patients With Chronic Viral Hepatitis Pre-treated With Vasopressin
Lead Sponsor:
National Taiwan University Hospital
Collaborating Sponsors:
National Science and Technology Council, Taiwan
Conditions:
Chronic Hepatitis C
Chronic Hepatitis B
Eligibility:
All Genders
Phase:
NA
Brief Summary
Percutaneous liver biopsy (PLB) is the gold standard for grading necroinflammation and staging fibrosis in patients with chronic viral hepatitis. Whether the use of 1-deamino-8-D-arginine vasopressin ...
Detailed Description
Chronic viral hepatitis is common in dialysis patients, with the reported prevalence and annual incidence of 3-80% and 2.9%, respectively. Currently, percutaneous liver biopsy (PLB) remains the gold s...
Eligibility Criteria
Inclusion
- Chronic hepatitis C (presence of anti-HCV and serum HCV RNA \> 6 months)
- Chronic hepatitis B (presence of HBsAg \> 6 months)
- Receiving regular hemodialysis or normal renal function (Creatinine \< 1.5 x ULN)
- Receiving percutaneous liver biopsy (PLB)
Exclusion
- Human immunodeficiency virus (HIV) co-infection
- Unwilling or contraindicated to receive percutaneous liver biopsy (PLB)
- Receiving liver biopsy without ultrasound (US) guidance or automatic cutting needles
- Did not receive 2 passes of liver biopsy
- Inadequate record of post-biopsy complications
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2013
Estimated Enrollment :
3520 Patients enrolled
Trial Details
Trial ID
NCT00635310
Start Date
January 1 2005
End Date
July 1 2013
Last Update
December 20 2012
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Chiayi Christian Hospital
Chiayi City, Taiwan
2
St. Martin De Porres Hospital
Chiayi City, Taiwan
3
National Taiwan University Hospital, Yun-Lin Branch
Douliu, Taiwan
4
Far Eastern Memorial Hospital
Taipei, Taiwan, 100